My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Abeona Therapeutics (ABEO)
NASDAQ:ABEO
ABEO nasdaq
United States
Abeona Therapeutics

Abeona Therapeutics Stock Analysis & Ratings

Abeona Therapeutics Stock Analysis Overview

Smart Score
3
Underperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Abeona Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

ABEO

ABEO Stock Stats

Previous Close$0.73
Open$0.82
Bid0.66 x 1970
Ask0.75 x 500
Today’s Range$0.64 - $0.8294
52-Week Range$0.64 - $3.79
Volume3.09M
Average Volume841.39K
Market Cap$65.74M
Beta1.38
P/E Ratio-1.3
EPS-0.57
Earnings DateMar 21, 2022

Company Description

Abeona Therapeutics

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
Sector
Healthcare
Industry
Biotechnology
CEO
Michael Amoroso
Employees
76
ISIN
US00289Y1073
Address
1330 Avenue of the Americas, New York, NY, 10019, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

ABEO FAQ

What was Abeona Therapeutics’s price range in the past 12 months?
Abeona Therapeutics lowest stock price was $0.64 and its highest was $3.79 in the past 12 months.
    What is Abeona Therapeutics’s market cap?
    Abeona Therapeutics’s market cap is $65.74M.
      What is Abeona Therapeutics’s price target?
      The average price target for Abeona Therapeutics is $2.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $4.00 ,the lowest forecast is $1.00. The average price target represents 287.60% Increase from the current price of $0.645.
        What do analysts say about Abeona Therapeutics?
        Abeona Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is Abeona Therapeutics’s upcoming earnings report date?
          Abeona Therapeutics’s upcoming earnings report date is Mar 21, 2022 which is in 111 days.
            How were Abeona Therapeutics’s earnings last quarter?
            Abeona Therapeutics released its earnings results on Nov 15, 2021. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.09.
              Is Abeona Therapeutics overvalued?
              According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
                Does Abeona Therapeutics pay dividends?
                Abeona Therapeutics does not currently pay dividends.
                What is Abeona Therapeutics’s EPS estimate?
                Abeona Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Abeona Therapeutics have?
                Abeona Therapeutics has 101,920,000 shares outstanding.
                  What happened to Abeona Therapeutics’s price movement after its last earnings report?
                  Abeona Therapeutics reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went down -5.435%.
                    Which hedge fund is a major shareholder of Abeona Therapeutics?
                    Among the largest hedge funds holding Abeona Therapeutics’s share is Wexford Capital LP. It holds Abeona Therapeutics’s shares valued at N/A.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis